FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2796107375> ?p ?o ?g. }

• W2796107375 endingPage "277" @default.
• W2796107375 startingPage "277" @default.
• W2796107375 abstract "In this issue of Cell and in papers appearing in Cell Reports, Cancer Cell, Cell Systems, and Immunity, we are proud to present the Pan-Cancer Atlas. The Pan-Cancer Atlas is the culmination of more than a decade of work from The Cancer Genome Atlas (TCGA) consortium. By analyzing over 11,000 tumors from 33 of the most prevalent forms of cancer (see SnapShot, page 530), the atlas provides a uniquely comprehensive, in-depth, and cohesive understanding of how, where, and why tumors arise in humans. TCGA has long been at the forefront of cancer-genome sequencing, but the effort also incorporates analysis of cancer transcriptomes, proteomes, methylomes, clinical data, and imaging. Through its integration of multiple data types and its ability to be mined for actionable information, the Pan-Cancer Atlas can be likened to a “Google Earth” for human cancer research. To open the collection, Carolyn Hutter and Jean Claude Zenklusen (page 283) provide an overview of the legacy of TCGA and the genesis of the Pan-Cancer Atlas project. The atlas consists of 27 papers divided into three categories: cell-of-origin patterns, oncogenic processes, and oncogenic pathways. Each category is anchored by a “marker” paper, appearing in Cell and providing a summary of the core findings for that topic. Multiple companion papers within these three categories explore individual subtopics in depth and are distributed among multiple Cell Press journals. To aid in navigating the expansive terrain the collection covers, we have created a dedicated web portal for readers and researchers (www.cell.com/consortium/pancanceratlas). Additionally, a webinar featuring project leaders Katherine Hoadley, Nikolaus Schultz, and Li Ding will provide a guided tour through some of the altas’s insights (http://www.cell.com/webinars). Among its numerous highlights, the Pan-Cancer Atlas reveals a new clustering of tumor types that will inform future clinical trials, grouping tumors based on molecular similarity and with a greater understanding of how their tissue of origin influences a cancer’s features. The collection also uncovers potential vulnerabilities that will aid in the development of combination therapies and personalized medicine. The atlas sheds new light on the collaboration between germline genetic variants and somatic mutations in cancer progression and the influence of mutation on cell signaling and immune-cell composition, which will help prioritize the development of new treatments and immunotherapies for a wide range of cancers. As a singular point of reference, the Pan-Cancer Atlas will have a long-term impact on setting priorities for new treatment development, combination therapies, and personalized medicine. Its data will be mined far into the future. The publication of the Pan-Cancer Atlas also signifies a major point of transition: the culmination of the decade-long TCGA effort (see Voices, page 281). To mark this turning point, Cell Press and TCGA are jointly organizing a Cell Symposium from September 27 to 29, 2018, in Washington, D.C. (http://www.cell-symposia.com/tcga-2018/) that will gather prominent speakers (including NIH Director Francis Collins), patient advocates, and other members of the cancer-research community. The meeting is open to all and will highlight the impact of TCGA and multi-omics on cancer research and provide a timely venue for the cancer community to discuss the future of multi-omics efforts. Publishing a large body of work is an intensive enterprise, and we would like to thank TCGA for their energy and collaborative spirit. Today, as we celebrate the achievements of TCGA, we would also like to take the opportunity at Cell Press to express our commitment and interest in partnering with consortia efforts generally. We are inspired by the collective effort and thinking that drive large-scale scientific collaborations and appreciate the immense value of the data they generate. We know from experience that consortia are diverse in both their make-up and goals and that their needs from a publishing partner are not one-size-fits-all. If you are part of a consortium, we would welcome hearing from you about your ideas, plans, and progress. This is true whether you have a package of papers fully formed and ready to submit, are applying for funding for a multi-lab or institute project, or even if your thoughts are simply percolating at the idea stage. Our goal, for individual papers and for larger collections, is to engage with researchers at all points of the scientific process. We hope you enjoy the Pan-Cancer Atlas and the other exciting work presented in this issue." @default.
• W2796107375 created "2018-04-13" @default.
• W2796107375 creator A5052337056 @default.
• W2796107375 date "2018-04-01" @default.
• W2796107375 modified "2023-10-16" @default.
• W2796107375 title "Charting a Course to a Cure" @default.
• W2796107375 doi "https://doi.org/10.1016/j.cell.2018.03.048" @default.
• W2796107375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29625043" @default.
• W2796107375 hasPublicationYear "2018" @default.
• W2796107375 type Work @default.
• W2796107375 sameAs 2796107375 @default.
• W2796107375 citedByCount "5" @default.
• W2796107375 countsByYear W27961073752018 @default.
• W2796107375 countsByYear W27961073752019 @default.
• W2796107375 countsByYear W27961073752020 @default.
• W2796107375 countsByYear W27961073752023 @default.
• W2796107375 crossrefType "journal-article" @default.
• W2796107375 hasAuthorship W2796107375A5052337056 @default.
• W2796107375 hasBestOaLocation W27961073751 @default.
• W2796107375 hasConcept C105702510 @default.
• W2796107375 hasConcept C136764020 @default.
• W2796107375 hasConcept C159985019 @default.
• W2796107375 hasConcept C192562407 @default.
• W2796107375 hasConcept C2522767166 @default.
• W2796107375 hasConcept C2776673561 @default.
• W2796107375 hasConcept C2780502288 @default.
• W2796107375 hasConcept C30407753 @default.
• W2796107375 hasConcept C41008148 @default.
• W2796107375 hasConcept C70721500 @default.
• W2796107375 hasConcept C86803240 @default.
• W2796107375 hasConceptScore W2796107375C105702510 @default.
• W2796107375 hasConceptScore W2796107375C136764020 @default.
• W2796107375 hasConceptScore W2796107375C159985019 @default.
• W2796107375 hasConceptScore W2796107375C192562407 @default.
• W2796107375 hasConceptScore W2796107375C2522767166 @default.
• W2796107375 hasConceptScore W2796107375C2776673561 @default.
• W2796107375 hasConceptScore W2796107375C2780502288 @default.
• W2796107375 hasConceptScore W2796107375C30407753 @default.
• W2796107375 hasConceptScore W2796107375C41008148 @default.
• W2796107375 hasConceptScore W2796107375C70721500 @default.
• W2796107375 hasConceptScore W2796107375C86803240 @default.
• W2796107375 hasIssue "2" @default.
• W2796107375 hasLocation W27961073751 @default.
• W2796107375 hasLocation W27961073752 @default.
• W2796107375 hasOpenAccess W2796107375 @default.
• W2796107375 hasPrimaryLocation W27961073751 @default.
• W2796107375 hasRelatedWork W136619100 @default.
• W2796107375 hasRelatedWork W1970302590 @default.
• W2796107375 hasRelatedWork W2082860237 @default.
• W2796107375 hasRelatedWork W2177859925 @default.
• W2796107375 hasRelatedWork W2627039752 @default.
• W2796107375 hasRelatedWork W2748952813 @default.
• W2796107375 hasRelatedWork W2898401212 @default.
• W2796107375 hasRelatedWork W2964767838 @default.
• W2796107375 hasRelatedWork W2990302163 @default.
• W2796107375 hasRelatedWork W3157701000 @default.
• W2796107375 hasVolume "173" @default.
• W2796107375 isParatext "false" @default.
• W2796107375 isRetracted "false" @default.
• W2796107375 magId "2796107375" @default.
• W2796107375 workType "article" @default.